{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:45:19Z","timestamp":1775493919628,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1124\/molpharm.120.000169","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T18:09:34Z","timestamp":1606846174000},"page":"147-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-8059","authenticated-orcid":false,"given":"Siennah R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond K.","family":"Hau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Jilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin Q.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Galligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-8997","authenticated-orcid":false,"given":"Daniel H.","family":"Foil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley M.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.120.000169_bib1","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1111\/bph.12748","article-title":"Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors","volume":"171","author":"Arimany-Nardi","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0028-3908(97)00136-6","article-title":"Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells","volume":"36","author":"Boleti","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.120.000169_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters-A review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1124\/molpharm.120.000169_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.rbmo.2020.04.009","article-title":"SARS-CoV-2 and the testis: similarity with other viruses and routes of infection","volume":"40","author":"Cardona Maya","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"10.1124\/molpharm.120.000169_bib5","first-page":"249","article-title":"Assessing agreement on classification tasks: the kappa statistic","volume":"22","author":"Carletta","year":"1996","journal-title":"Comput Linguist"},{"key":"10.1124\/molpharm.120.000169_bib6","doi-asserted-by":"crossref","first-page":"49786","DOI":"10.18632\/oncotarget.10448","article-title":"FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia","volume":"7","author":"Catal\u00e0","year":"2016","journal-title":"Oncotarget"},{"key":"10.1124\/molpharm.120.000169_bib7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/acs.jcim.5b00143","article-title":"Open source bayesian models. 1. Application to ADME\/tox and drug discovery datasets","volume":"55","author":"Clark","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1124\/molpharm.120.000169_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.jcim.5b00144","article-title":"Open source bayesian models. 2. Mining a \u201cbig dataset\u201d to create and validate models with ChEMBL","volume":"55","author":"Clark","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1124\/molpharm.120.000169_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/mol.105.021543","article-title":"The role of human nucleoside transporters in cellular uptake of 4\u2032-thio-\u03b2-D-arabinofuranosylcytosine and \u03b2-D-arabinosylcytosine","volume":"70","author":"Clarke","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Psychol Meas"},{"key":"10.1124\/molpharm.120.000169_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4939-1862-1_10","article-title":"Genome engineering using CRISPR-Cas9 system","volume":"1239","author":"Cong","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1124\/molpharm.120.000169_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bj2000295","article-title":"Binding of nitrobenzylthioinosine to high-affinity sites on the nucleoside-transport mechanism of HeLa cells","volume":"200","author":"Dahlig-Harley","year":"1981","journal-title":"Biochem J"},{"key":"10.1124\/molpharm.120.000169_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/15257770.2011.652330","article-title":"Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine","volume":"31","author":"Damaraju","year":"2012","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1124\/molpharm.120.000169_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2014.10.001","article-title":"Apical ABC transporters and cancer chemotherapeutic drug disposition","volume":"125","author":"Durmus","year":"2015","journal-title":"Adv Cancer Res"},{"key":"10.1124\/molpharm.120.000169_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"5","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1124\/molpharm.120.000169_bib16","unstructured":"European Medicines Agency Committee for Human Medicinal Products (2012) Guideline on the investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"10.1124\/molpharm.120.000169_bib17","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"key":"10.1124\/molpharm.120.000169_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.chembiol.2019.11.005","article-title":"Non-enzymatic lysine lactoylation of glycolytic enzymes","volume":"27","author":"Gaffney","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1124\/molpharm.120.000169_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-4157(96)00008-1","article-title":"Nucleoside and nucleobase transport systems of mammalian cells","volume":"1286","author":"Griffith","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/molpharm.120.000169_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0022-3565(24)38072-3","article-title":"[3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line","volume":"288","author":"Hammond","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000169_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-200060020-00015","article-title":"Abacavir: a review of its clinical potential in patients with HIV infection","volume":"60","author":"Hervey","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/molpharm.120.000169_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bdd.2131","article-title":"Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells","volume":"39","author":"Hioki","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/molpharm.120.000169_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138920009788499030","article-title":"Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity","volume":"10","author":"Huber-Ruano","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/molpharm.120.000169_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/molpharm.120.000169_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1124\/molpharm.120.000169_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/molpharm.120.000169_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/jpet.104.073387","article-title":"Nucleoside transport at the blood-testis barrier studied with primary-cultured sertoli cells","volume":"312","author":"Kato","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000169_bib29","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1021\/jm2001629","article-title":"Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2","volume":"54","author":"Kido","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.120.000169_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209104","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer","volume":"13","author":"Kim","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.120.000169_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/jpet.113.203265","article-title":"Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1","volume":"346","author":"Klein","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.120.000169_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/17425255.2012.680885","article-title":"The role of transporters in the toxicity of nucleoside and nucleotide analogs","volume":"8","author":"Koczor","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/molpharm.120.000169_bib34","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.molpharmaceut.8b00083","article-title":"Mycobacterium tuberculosis drug discovery","volume":"15","author":"Lane","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/molpharm.120.000169_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0026-895X(25)12451-6","article-title":"Binding of the nucleoside transport inhibitor nitrobenzylthioinosine to HeLa cells","volume":"13","author":"Lauzon","year":"1977","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib36","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1365-2605.2009.00973.x","article-title":"HIV infection of the male genital tract - consequences for sexual transmission and reproduction","volume":"33","author":"Le Tortorec","year":"2010","journal-title":"Int J Androl"},{"key":"10.1124\/molpharm.120.000169_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8292","article-title":"Clinical characteristics and results of semen tests among men with coronavirus disease 2019","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1124\/molpharm.120.000169_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-\u0394 \u0394 C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1124\/molpharm.120.000169_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.4449","article-title":"HIV and the spectrum of human disease","volume":"235","author":"Lucas","year":"2015","journal-title":"J Pathol"},{"key":"10.1124\/molpharm.120.000169_bib40","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/91.21.1876","article-title":"Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters","volume":"91","author":"Mackey","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/molpharm.120.000169_bib41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0005-2795(75)90109-9","article-title":"Comparison of the predicted and observed secondary structure of T4 phage lysozyme","volume":"405","author":"Matthews","year":"1975","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/molpharm.120.000169_bib42","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/REP-18-0338","article-title":"Transepithelial transport across the blood-testis barrier","volume":"156","author":"Miller","year":"2018","journal-title":"Reproduction"},{"key":"10.1124\/molpharm.120.000169_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/dmd.120.090720","article-title":"Nucleoside reverse transcriptase inhibitor interaction with human equilibrative nucleoside transporters 1 and 2","volume":"48","author":"Miller","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/molpharm.120.000169_bib44","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/er.2014-1101","article-title":"The mammalian blood-testis barrier: its biology and regulation","volume":"36","author":"Mruk","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1124\/molpharm.120.000169_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2010.11.007","article-title":"Emerging role for drug transporters at the blood-testis barrier","volume":"32","author":"Mruk","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.120.000169_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","author":"Pastor-Anglada","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jcp.1040970107","article-title":"Uridine transport in novikoff rat hepatoma cells and other cell lines and its relationship to uridine phosphorylation and phosphorolysis","volume":"97","author":"Plagemann","year":"1978","journal-title":"J Cell Physiol"},{"key":"10.1124\/molpharm.120.000169_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0005-2736(84)90548-0","article-title":"Nucleoside transport in cultured mammalian cells. Multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine","volume":"773","author":"Plagemann","year":"1984","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/molpharm.120.000169_bib49","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1124\/molpharm.120.000169_bib50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/2472555219870123","article-title":"Current progress on equilibrative nucleoside transporter function and inhibitor design","volume":"24","author":"Rehan","year":"2019","journal-title":"SLAS Discov"},{"key":"10.1124\/molpharm.120.000169_bib51","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume":"132","author":"Rozen","year":"2000","journal-title":"Methods Mol Biol"},{"key":"10.1124\/molpharm.120.000169_bib52","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1021\/acs.molpharmaceut.8b00546","article-title":"Comparing multiple machine learning algorithms and metrics for estrogen receptor binding prediction","volume":"15","author":"Russo","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/molpharm.120.000169_bib53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1124\/mol.117.111443","article-title":"Assessment of substrate-dependent ligand interactions at the Organic Cation Transporter OCT2 using six model substrates","volume":"94","author":"Sandoval","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000169_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/156800911793743600","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)","volume":"11","author":"Santini","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1124\/molpharm.120.000169_bib55","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1002\/jps.24498","article-title":"Saturable hepatic extraction of gemcitabine involves biphasic uptake mediated by nucleoside transporters equilibrative nucleoside transporter 1 and 2","volume":"104","author":"Shimada","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1124\/molpharm.120.000169_bib56","doi-asserted-by":"crossref","first-page":"45270","DOI":"10.1074\/jbc.M107169200","article-title":"Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs","volume":"276","author":"Sundaram","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000169_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/bdd.2110","article-title":"Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine","volume":"39","author":"Takahashi","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/molpharm.120.000169_bib58","unstructured":"United States Department of Health and Human Services (2017) In vitro metabolism and transporter-mediated drug-drug interaction studies guidance for industry draft guidance. In, Food and Drug Administration Center for Drug Evaluation and Research. Research, ed. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions"},{"key":"10.1124\/molpharm.120.000169_bib59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/bjc.2017.187","article-title":"Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma","volume":"117","author":"Vincenzi","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1124\/molpharm.120.000169_bib60","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000169_bib61","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1172\/JCI112823","article-title":"Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells","volume":"79","author":"White","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1124\/molpharm.120.000169_bib62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0277-5379(83)90029-9","article-title":"Cytosine arabinoside transport by human leukaemic cells","volume":"19","author":"Wiley","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1124\/molpharm.120.000169_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/09687680110048318","article-title":"Transport of antiviral 3\u2032-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes","volume":"18","author":"Yao","year":"2001","journal-title":"Mol Membr Biol"},{"key":"10.1124\/molpharm.120.000169_bib64","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.molpharmaceut.8b01297","article-title":"Multiple machine learning comparisons of HIV cell-based and reverse transcriptase data sets","volume":"16","author":"Zorn","year":"2019","journal-title":"Mol Pharm"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.120.000169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:36:45Z","timestamp":1739961405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24011222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0026895X24011222"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.120.000169","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.120.000169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}